# Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer

> **NCT06603376** · PHASE2 · RECRUITING · sponsor: **Shanghai Changzheng Hospital** · enrollment: 75 (estimated)

## Conditions studied

- Colorectal Carcinoma

## Interventions

- **DRUG:** FOLFIRI + Vemurafenib + Cetuximab
- **DRUG:** FOLFIRI ± Bevacizumab

## Key facts

- **NCT ID:** NCT06603376
- **Lead sponsor:** Shanghai Changzheng Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-01
- **Primary completion:** 2026-08-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06603376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06603376, "Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06603376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*